5th European Summer School. Drug interactions. therapeutic Information
|
|
- Lucinda Chase
- 6 years ago
- Views:
Transcription
1 Gent, August 25, th European Summer School EACPT Drug interactions Marc Bogaert Belgian Centre for Pharmaco- therapeutic Information ( be)
2
3
4
5 Interactions -Preliminary remarks -Mechanisms -The risk situations and risk classes -The lists : sources of information and their discrepanciesi -Some examples for drug classes -Some examples of clinical consequences -Conclusions
6 Interactions : preliminary remarks -Interactions between drugs, but also between drugs and food, drink, alcohol, herbs -Some effects are wanted (e.g. cardiovascular, oncology, HIV), but often the consequences of an interaction are unwanted -The effect can be increased (with side-effects) or decreased (with possible loss of efficacy) during or after concomitant use -The interest should go mainly to drugs with a narrow toxic-therapeutic range or important intrinsic toxicity -Clinical relevance : severity and frequency
7 Interactions : mechanisms -Pharmaceutical interactions -Pharmacodynamic interactions -Pharmacokinetic interactions P.S. Interaction problems are often both pharmacodynamic and pharmacokinetic
8 The pharmacodynamic interactions -Occur at the level of the cells (e.g. receptors) or are due to interference with reflex adaptations of the organism (e.g. cardiovascular, central nervous system) -Often class effect, but -Often predictible based on the pharmacodynamic effect, but -More difficult to study than pharmacokinetic interactions and therefore often neglected
9 The pharmacokinetic interactions With a precipitant drug and an object drug -Absorption -Distribution -Renal excretion -Biotransformation P.S. Interactions at the level of P-glycoprotein gy (PgP)
10 The pharmacokinetic i interactions i : absorption -Influence on the absorption rate (with changes in peak concentration which can be relevant) and/or the total absorption (AUC) -Via an influence on gastric ph or emptying, adsorption, chelation P.S. Influences on intestinal first-pass (e.g. grapefruit)
11 The pharmacokinetic interactions : distribution -Changes of tissue binding or plasma protein binding -Changes of plasma protein binding can lead to changes in free fraction, but in vitro experiments tend to overestimate this phenomenon (often high concentrations ti are tested) t -For a given change in free fraction, there is often less change in free concentration, due to compensatory mechanisms (distribution, elimination)
12 The pharmacokinetic interactions : renal excretion -Changes in ph and tubular reabsorption Competition for active pumps (e g probenecid -Competition for active pumps (e.g. probenecid versus penicillins)
13 The pharmacokinetic interactions : biotransformation -Biotransformation takes place mainly in the liver but also elsewhere (e.g. intestinal wall, important for first-pass) -There is much interest for the cytochrome P450 iso-enzymes
14 The cytochrome P450 iso-enzymes -A number of families (> 36 % homology of the aminoacid sequence) e.g. eg CYP2 -With in each family a number of subfamilies (> 77 % homology) e.g. CYP2D -With in each subfamily a number of specific enzymes e.g. CYP2D6
15 The human cytochrome P450 iso-enzymes FAMILY SUBFAMILY A A B C D E F A ENZYME 1A1 2A6 2B6 2C8 2D6 2E1 2F1 3A4 1A2 2A7 2B7 2C9 3A5 2A13 2C18 3A7 2C19
16 The CYP S : a few comments -Large interindividual variability (genetic and acquired), with genetic polymorphism for CYP2D6, CYP2C9, CYP2C19 -A drug can be metabolized by one or by several CYP s -A drug can inhibit or induce one or several CYP s -Drugs (and other substances) can be potent or less potent inhibitors or inducers P.S. The important t CYP interactions ti : how to decide?
17
18 The CYP s : important inducers and inhibitors CYP1A2 CYP2C9 Inhib. : fluvoxamine Inducers : barbiturates, carbamazepine, phenytoïn, rifampicin in Inhib. : miconazol,,phenylbutazon Inducers : barbiturates, carbamazepine, phenytoïn, rifampicin CYP2C19 Inhib. : fluvoxamine CYP2D6 CYP3A4 Inhib. : bupropion, fluoxetine, paroxetine, propafenone, quinidine, ritonavir, terbinafine Inhib. : clarithromycin, erythromycin, grapefruit, itraconazol, ketoconazol, proteaseinhibitors, voriconazol Inducers : carbamazepine, rifampicin, i i St.John s Wort
19 Interactions at the level of the CYP s -The concentrations of the object drug can be changed by CYP induction or inhibition -The change is mainly important when the object drug is metabolized by only one CYP, and the precipitant drug is a potent inducer or inhibitor -The interaction often takes place at the level of gut or liver first-pass
20 Interactions at the level of P-glycoprotein (PgP) -PgP is an active efflux pump, localized in plasma membranes (gut, liver, kidney, brain ) -There is a marked overlap between substrates, inducers and inhibitors for CYP3A4, and those for PgP (with exceptions, e.g. digoxin) -Substrates : anti-cancer drugs, calcium entry blockers, digoxin, immunomodulators, HIV-protease inhibitors -Inhibitors : erythromycin, ketoconazol, quinidine, verapamil, ciclosporin, (grapefruit juice?) -Inductors : rifampicin, phenobarbital, St. John s Wort
21
22
23 The risk situations s for interactions -Polymedication -Old age -Presence of renal failure, heart failure (e.g. for NSAID s and ACE-inhibitors), asthma -Drugs undergoing marked first-pass (gut, liver) -Drugs with narrow therapeutic-toxic ti t i margin -Drugs with high intrinsic toxicity -Use of high doses -Certain classes of drugs
24 Drug classes with high risk for interactions -Anti-arrhythmics -Beta-blockers boc e -Anticoagulants -Anticonceptives -Digitalis -Anti-epileptic il drugs -NSAID s -H1-antihistaminics -Anti-HIV drugs -Antimycotic drugs -Immunosuppressants -Statins -Triptans
25 The sources of information - Summary of product characteristics - Martindale - Stockley s Drug Interactions - Hansten and Horn : The Top 100 drug interactions - Meyler s Side Effects of Drugs - La Revue Prescrire, suppl. : Interactions médica- menteuses, comprendre et décider British National Formulary P.S. The discrepancies between sources
26
27
28 Drug interactions sources : the discrepancies -Aronson J.K. : Communicating information about drug interactions. Br J Clin Pharmacol 2007;63: Vitry A.I. : Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63: There is a lack of consistency in the inclusion and grading of drug interactions of major significance for 50 drugs across the four drug compendia examined. This may reflect the lack of standardization of the terminology used to classify drug interactions and the lack of good epidemiological evidence on which to base the assessment of the clinical relevance of drug interactions.
29 Drug interactions sources : the discrepancies The lack of good evidence -Difficulties : large number of possible combinations, intra-individual variability, in vitro versus in vivo, doses used, individual drug versus drug class, case-reports, unfrequent events -Information o sources s should indicate the quality of the evidence, e.g. as proposed by Aronson, Br J Clin Pharmacol 2007;63:637-9 : A : anecdotes D : data from laboratory experiments or extrapolated from theory R : randomised trials or observational studies But : quality of the evidence!
30 Drug interactions sources : the discrepancies Problems of terminology Hansten and Horn 2005 Class 1 : Avoid Combination (Risk of combination outweighs benefit) Class 2 : Usually Avoid Combination (Use only under special circumstances) Class 3 : Minimize Risk (Assess risk and take one or more of the following actions if needed) Class 4 : No Special Precautions (Risk of adverse outcome appears small) Class 5 : Ignore (Evidence suggests that the drugs do not interact) (cont.)
31 Drug interactions sources : the discrepancies Problems of terminology (cont.) -The decision to allocate a certain interaction to one of the Hansten and Horn classes is in most cases arbitrary -There are a few examples of true class 1 interactions (to be avoided in all circumstances) but for many of the interactions mentioned by Hansten and Horn, it is difficult to decide between classes 1 and 2, between classes 2 and 3, between classes 3 and 4
32 Interactions : some examples for drug classes -Antidepressant drugs -Coumarine anticoagulants -Statins -NSAID s -Oral contraceptives -Anti-Alzheimer drugs P.S. : - alcohol - grapefruit - herbs (e.g. St. John s Wort)
33 Antidepressant drugs -The serotonin syndrome (cfr. below) -First and second generation antidepressants effect of central antihypertensives, sedation, anticholinergic effects by other drugs or biotransformation (CYP s) -SSRI s interactions via CYP s fluoxetin : inhibits 2D6, 2C19, 3A4 fluvoxamine : inhibits 1A2, 2C9, 3A4 paroxetine : inhibits 2B6 citalopram, escitalopram, sertraline : no? increased risk of GI bleeding with NSAID s (and ASA) - St. John s Wort : induction of CYP3A4 (and PgP?)
34 Coumarine anticoagulants - The pharmacodynamic interactions with other drugs interfering with coagulation - The pharmacokinetic interactions (mainly via CYP2C9) : certainly for warfarine, possibly also for acenocoumarol; less for fenprocoumon P.S. With increased (bleeding) or decreased (lack of efficacy) effect : mainly at the moment of starting or stopping the precipitant drug
35 Statins - The statins (and also ezetimibe) are toxic for the muscle cells, with risk of myalgia and rhabdomyolysis (risk factors : high doses, renal failure, alcohol use, old age) - More risk due to interactions. Pharmacodynamic : + fibrates, + ezetimibe. Pharmacokinetic : atorvastatine and simvastatine : conc. with CYP3A4-inhibitors fluvastatine conc. with ih CYP2C9-inhibitors. Unknown mechanism : all statins + ciclosporine
36
37 Lady 87 years Rhabdomyolysis by simvastatin (Belgian Centre for Pharmacovigilance) -Since one year simvastatin 40 mg per day -During one week itraconazole 200 mg per day for intertrigo -Two and a half weeks after stopping itraconazole : rhabdomyolysis and acute renal failure, and death High dose of simvastatin, CYP3A4 inhibition by itraconazol, in the presence of decreased renal function (age!) P.S. Rational prescribing?
38 Non-steroidal anti-inflammatory drugs Pharmacokinetic interactions - Displacement of other drugs (e.g. coumarin anticoagulants from plasma proteins)? - Decreased excretion of lithium Pharmacodynamic interactions - Increased risk of gastric bleeding when given with glucocorticoids - Increased risk of GI bleeding with SSRI s - Less effect of diuretics and antihypertensives - nefrotoxicity of ciclosporine - hyperkalaemia (cfr.) - cardioprotective effect of aspirine? P.S. Loss of the GI advantage of COX-2-NSAID s by low dose aspirin?
39 Concomitant use of ibuprofen and aspirin (FDA information for health care professionals) Patients who use immediate release aspirin (not enteric coated) and take a single dose of ibuprofen 400 mg should dose the ibuprofen at least 30 minutes or longer of aspirin s s effect. Recommendations about the timing of concomitant use of ibuprofen and enteric-coated t low dose aspirin i cannot be made based upon available data. Other nonselective OTC NSAIDs should be viewed as having the potential to interfere with the antiplatelet effect of low-dose aspirin unless proven otherwise.
40 Interactions with loss of anticonceptive effect of oral estroprogestative contraceptives - Induction of CYP3A4 by barbiturates, carbamazepine and oxcarbazepine, felbamate, fenyturide, fenylbutazon, fenytoïne, griseofulvine, primidon, rifampicin en rifabutin, ritonavir, topiramate Also by St. John s Wort (breakthrough bleeding; pregnancy?) - Antibiotics other than rifampicine and rifabutin P.S. Difficulty of proving that pill failure is due to an interaction, and not e.g. to lack of compliance
41 Interactions with cholinesterase-inhibitors as anti-alzheimer drugs - Pharmacodynamic. with drugs with an anticholinergic i effect (cognitive deterioration and urinary problems). with neuroleptics (extrapyramidal symptoms and increased mortality). with cardiac drugs (bradycardia, di conduction disorders) - Pharmacokinetic. rivastigmine : no. donepezil and galantamine : more unwanted effects when CYP3A4-inhibitors or CYP2D6- inhibitors are associated S h d ff P.S. How to recognize such side-effects in an elderly population?
42 Interactions with alcohol Pharmacodynamic interactions. with drugs with effects on the CNS. with hypoglykemic drugs, antihypertensives, antithrombotic t drugs. with paracetamol in overdosis Pharmacokinetic interactions ti. as object drug : increased alcohol concentration with i.a. cimetidine; disulfiram reactions. as precipitant drug : with acute use inhibition of drug biotransformation; ti with chronic use enzyme induction P.S. Often pharmacodynamic + pharmacokinetic
43 Interactions with grapefruit (juice) - Mainly inhibition of CYP3A4 in the gut wall (first- pass, not hepatic) - Leads to increased concentrations of the object drugs - Active substance? -How much juice? -Composition of the juice? - For how long is the interaction present? (long) - Substrates : see following slide P.S.- Can this be used to decrease the dose of drugs which are difficult to manufacture? - The interaction does not occur with other juices
44 Interactions with grapefruit (juice) (cont.) Important substrates for CYP3A4 - Calcium antagonists t - Benzodiazepines with first pass (triazolam, diazepam) - Psychotropic agents (buspirone, carbamazepine) - Statins ti (simvastatine, ti lovastatine, ti atorvastatine) t ti - Phosphodiësterase type 5-inhibitors (e.g. Viagra )
45
46 Interactions drugs-herbs - Certainly not unfrequent i.a. ginkgo biloba, Allium sativum, ginseng, senna, cascara, cranberry juice, St. John s Wort (see La Revue Prescrire 2007, vol. 286, numéro spécial Bien utiliser les plantes en situations de soins ) - Special attention for St. John s Wort (Hypericum perforatum) :. Serotonin syndrome (cfr). Induces CYP3A4, possibly also P-glycoproteïn
47
48 Interactions : some examples of clinical consequences - Cardiovascular or central depression with numerous combinations of drugs - QT-prolongation and torsades de pointes - Serotonin syndrome - Hyperkalaemia
49 QT-prolongation - QT-prolongation can cause torsades de pointes and death - Which drugs can prolong the QT-interval? i.a. class I and III-anti-arrhythmics, cisapride, ketanserin,some some neuroleptics, amfotericine B, pentamidine, erythromycine intravenously (and possibily also clarithromycine), telithromycine, levofloxacine and moxifloxacine, methadon P.S. The H1-antihistaminics other than terfenadine (Triludan) and astemizol (Hismanal)?
50 QT-prolongation : risk situations for torsades de pointes - Bradycardia, hypokalaemia, congenital QTprolongation, overdose, cardiac disease - Interactions. Combination of drugs which prolong the QT- interval. Combination of a drug which prolongs the QT- interval + an inhibitor of its metabolism (important e.g. for cisapride, erythromycine y intravenously). Combination of a drug which prolongs the QT- interval + a potassium losing diuretic
51 A case report A 20 year old lady consults her general practitioner for recurrent vaginal mycosis. R/itraconazole Before leaving, she mentions an itching skin lesion R/terfenadine (an H 1 -antihistaminic) Two days later, she is found death in her bed Probably torsades de pointes : terfenadine (which is cardiotoxic) is a pro-drug which is in first-pass after oral administration almost completely metabolized (CYP3A4) to the active fexofenadine, but in overdose or if CYP3A4 is inhibited (e.g. by itraconazole), terfenadine reaches the systemic circulation
52 The serotonin syndrome - Symptoms : confusion, hyperthermia, myoclonus, salivation, tremor (difficult to differentiate from delirium and from malignant neuroleptic syndrome) - Can occur with drugs which increase the serotonin concentration at the level of the receptors (tryptophan, MAO-inhibitors, amfetamines, SSRI s, sibutramine, TCA s, lithium, St. John s Wort ) - Usually only seen when several of these drugs are given concomitantly (Boyler and Shannon, NEJM 2005, vol. 352, pp )
53 Hyperkalaemia - Consequences : heart, striated muscle - Mainly in patients t with renal failure (e.g. elderly) l - More risks when several drugs are given concomitantly. Potassium supplements, potassium sparing diuretics. ACE-inhibitors, sartans. NSAID s. Ciclosporine, tacrolimus. Heparin. Erythropoietine P.S. Spironolacton (> 50 mg) in association with ACEinhibitors or sartans for treatment of cardiac failure (BMJ 2003, vol. 327, pp )
54 Conclusions - Evidence about interactions ti is often lacking - The terminology for communication is often unclear - Not all interactions deserve the same attention (severity, frequency) - Knowing the mechanism is helpful - Avoid polypharmacy - Monitoring the patient is important - Where to find the correct information at the moment of prescription? Prescription aids?
Drug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationA. Definition. B. Epidemiology. C. Classification. i. Pharmacokinetic DIs. ii. Pharmacodynamic DIs. D. Recognition. E. Prevention
DRUG OUTLINE A. Definition B. Epidemiology Dr Ruwan Parakramawansha MBBS, MD, MRCP(UK),MRCPE, DMT(UK) (2013/09/05) C. Classification i. Pharmacokinetic DIs ii. Pharmacodynamic DIs D. Recognition E. Prevention
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationCOMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona
COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS Dan Malone, RPh, PhD Professor University of Arizona Disclosures I, Daniel Malone, have no financial relationships to disclose
More informationDorset Health Technologies Forum SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA )
INDICATION SHARED CARE GUIDELINE FOR PRESCRIBING EPLERENONE (INSPRA ) Eplerenone is an aldosterone antagonist licensed to be used in addition to standard therapy including beta-blockers, to reduce the
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and
More informationDrug Interactions: Let me count the ways
: Let me count the ways President: PRN Associates, Ltd. Continuing Education in Pharmacology Tucson, AZ Objectives At the conclusion of this continuing education lesson, the participant will be able to:
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationPsychotropic Drug Interactions Over the past 2 decades:
Psychotropic Drug Interactions Over the past 2 decades: Treatment options: Several and non- therapies Increasing number of psychotropic s Increased risk of adverse outcomes Overwhelming information on
More informationCytokrom P450 (CYP) Hepatic Drug Metabolism. Medicines in plasma. Plasma concentration of a medicine. Eva Brittebo Dept Pharmaceutical Biosciences
Hepatic Drug Metabolism Eva Brittebo Dept Pharmaceutical Biosciences Background Cytochrome P450 (CYP) Liver metabolism Liver toxicity Inhibition and induction Polymorphism 15-05-13 2 Plasma concentration
More informationThere is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.
amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Frequently Asked Questions: Table of Contents How should pain be assessed in an unconscious patient? What is the cardiovascular risk associated with the use of nsnsaids/coxibs
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationObjectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner
Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner Wendy L. Wright, MS, ANP-BC, FNP-BC, FAANP, FAAN, FNAP Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst,
More informationDrug Interactions for the Emergency Physician. Lisa Thurgur
Drug Interactions for the Emergency Physician Lisa Thurgur Objectives Why we should care about drug-drug interactions Cases How can we avoid these interactions Short list of culprit drugs Drug-Drug Interaction
More informationLapatinib and capecitabine for breast cancer Funding arrangements to be set up and specified locally Page 1 of 5
Indication: Funding arrangements to be set up and specified locally Page 1 of 5 Lapatinib in combination with Capecitabine is recommended as a treatment option for people with advanced and/or metastatic
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More information12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.
Drug Interactions Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc. Boston, MA, USA December 10, 2015 1 1 Overview Epidemiology and Categories of Drug
More informationThe Case of Libby Zion and Dangerous Drug Interactions
The Case of Libby Zion and Dangerous Drug Interactions J.R.White, PA, PharmD I. MAOI and Meperidine Libby Zion 18 yo female Rx c phenelzine (Nardil) Meperidine given for shaking chills Outcome Death Libby
More informationImportance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie
More informationWho remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?
Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened
More informationEFFECTIVE SHARED CARE AGREEMENT. Dronedarone - For the treatment and management of atrial fibrillation
EFFECTIVE SHARED CARE AGREEMENT Dronedarone - For the treatment and management of atrial fibrillation Specialist details Patient identifier Name INTRODUCTION This shared care agreement outlines how the
More informationDrug Intractions Alessandro Nobili Luca Pasina Claudia Braun What does the term drug interaction mean?
Drug Intractions edited by Alessandro Nobili e Luca Pasina Laboratorio di valutazione della Qualità delle Cure e dei Servizi per l Anziano Servizio Informazione sui Farmaci nell Anziano Translated and
More informationDrug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health December 9, 2010 Drug Interactions:
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE INVESTIGATION OF DRUG INTERACTIONS
The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit London, 17 December, 1997 CPMP/EWP/560/95 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE
More informationRISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationTherapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University
Therapeutic drug monitoring Department of Clinical Pharmacology, Wrocław Medical University Therapeutic index concentration range characterized by a high efficacy of action and low risk of upper toxic
More informationPolypharmacy and Common Drug Interactions in Geriatric Patients
Polypharmacy and Common Drug Interactions in Geriatric Patients Jasmine Cutler, Pharm.D., CPh USF Health Byrd Alzheimer s Institute Assistant Professor, USF College of Pharmacy May 19, 2017 Today s 4 Objectives
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationeview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution
Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP Presented at the University of Saskatchewan s 4th Annual Peter and Anna Zbeetnoff Memorial Drug Therapy Decision-Making Conference,
More informationDRUGS, PREGNECY & NEWBORN
DRUGS, PREGNANCY & NEWBORN DRUGS, PREGNECY & NEWBORN By- Dr Raghuveer Ist By- PG Dept of Rasashastra Dr Raghuveer Dept of Rasashastra KVG Ayurvedic Medical College Sullia ayuraghu@rediffmail.com Introduction
More informationSUMMARY OF PRODUCT CHARACTERISTICS
WHOPAR part 4 January 2017 Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 30 WHOPAR part 4 January 2017 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT * 2. QUALITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS
Section 6 updated: March 2017 SUMMARY OF PRODUCT CHARACTERISTICS 1 Section 6 updated: March 2017 1. NAME OF THE MEDICINAL PRODUCT Ritonavir Tablets 100 mg * 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationPHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS
1 PHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS OBJECTIVES 2 Know and understand: Key issues in geriatric pharmacology Effects of age on pharmacokinetics
More informationAntibiotic Class Interacting Drug Comment Penicillins e.g. Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin
Antibiotic Class Interacting Drug Comment Penicillins Methotrexate Amoxicillin Co amoxiclav Flucloxacillin Phenoxymethylpenicillin Cephalosporins Cefaclor Cefixime Cefuroxime Cephalexin Cefazolin* Ceftriaxone*
More informationInterface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE
Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable
More informationAn interaction occurs when the effects of one drug are changed by the presence of another drug, food, drink or by some environmental chemical agent.
Drug Interactions Definition An interaction occurs when the effects of one drug are changed by the presence of another drug, food, drink or by some environmental chemical agent. Drug-drug interactions
More informationValproate Case 1: Pharmacokinetics Jose de Leon, MD
Valproate Case 1: Pharmacokinetics 2-12-16 Jose de Leon, MD 1. Valproate Case 1 J Clin Psychopharmacology 2009;29:509-11 http://www.ncbi.nlm.nih.gov/pubmed/19745660 Educational Objectives At the conclusion
More informationPharmacology in the Elderly
Pharmacology in the Elderly James Hardy Geriatrician, Royal North Shore Hospital A recent consultation Aspirin Clopidogrel Warfarin Coloxyl with senna Clearlax Methotrexate Paracetamol Pantoprazole Cholecalciferol
More informationInitiation Guide. Images not actual size.
Initiation Guide Images not actual size. INDICATIONS AND USAGE SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation
More informationEach film-coated tablet contains 12.5 mg of ombitasvir, 75 mg of paritaprevir and 50 mg of ritonavir.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
More informationTitle of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)
Author of Lecture: Hilmer, Sarah (Dr.) Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009) COMMONWEALTH OF AUSTRALIA Copyright Regulations 1969 WARNING This material
More informationPrescribing Drugs to the Elderly
Answers to your questions from University of Toronto experts Prescribing Drugs to the Elderly Can drugs do more harm than good? M.A. is a 90-year-old man living at home. He has dementia and due to wandering
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Oral solution 10 mg /ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Oral solution 10 mg /ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY PROFILE Based on EU SmPC sections
More informationTABLE OF CONTENTS. COX-2 Inhibitors Cardiovascular and Gastrointestinal Safety
TABLE OF CONTENTS COX-2 Inhibitors - Cardiovascular and Gastrointestinal Safety 1-2 Oral Erythromycin and Risk of Sudden Cardiac Death 2-3 Common Drug Interactions between Herbal and Prescription Medications
More informationDrug-Drug Interactions in Psychiatry
Drug-Drug Interactions in Psychiatry John J. Miller, M.D. Medical Director, Brain Health Exeter, NH Acknowledgement Some of the slides used in this presentation were created by Jessica R. Oesterheld, MD.
More informationPackage leaflet: Information for the patient. VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride)
Package leaflet: Information for the patient VEPROL Film coated tablets 40 mg or 80 mg (Verapamil hydrochloride) Read this leaflet carefully before you start taking this medicine. - Keep this leaflet.
More informationTreatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society
Treatments for stroke prevention in Atrial Fibrillation as recommended by the Canadian Cardiovascular Society Coumadin (Warfarin) Does this medication need ongoing monitoring of blood clotting times? Yes.
More informationInteractions Between Herbal Medicines and Prescribed Drugs
REVIEW ARTICLE Drugs 2009; 69 (13): 1777-1798 0012-6667/09/0013-1777/$55.55/0 ª 2009 Adis Data Information BV. All rights reserved. Interactions Between Herbal Medicines and Prescribed Drugs An Updated
More informationOBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics
PHARMACOTHERAPY 1 OBJECTIVES 2 Know and understand: Key issues in geriatric pharmacology Effects of age on pharmacokinetics and pharmacodynamics Risk factors for adverse drug events for older patients
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.
Systemic Anti Cancer Treatment Protocol Tivozanib PROTOCOL REF: MPHATIVOUR (Version No: 1.0) Approved for use in: Tivozanib is indicated for the first line treatment of advanced / metastatic renal cell
More information12/19/16. Disclosures
@atriumrx Don t Miss a Beat! Practical Tips on Managing Drug-Induced QTc Prolongation Sandeep Devabhakthuni, PharmD, BCPS- AQ Cardiology Assistant Professor University of Maryland School of Pharmacy Disclosures
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml. Date of FAR:
Core Safety Profile Active substance: Itroconazole Pharmaceutical form(s)/strength: Concentrate and solvent for solution for infusion, 10mg/ml P - RMS: UK/H/PSUR/0033/001 Date of FAR: 15.07.2010 CORE SAFETY
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationQuetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD
Quetiapine Case 2 Therapeutic Drug Monitoring 1-27-16 Jose de Leon, MD 2. Quetiapine Case Therapeutic Drug Monitoring (unpublished) Educational Objectives At the conclusion of this presentation, the participant
More informationKiller Drug Interactions. Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional
Killer Drug Interactions Karen Curzio Rodeghiero, PharmD, BCPS Clinical Pharmacist, Emergency Medicine Piedmont Athens Regional Disclosure I have no financial interests or relationships to disclose Primum
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lercanidipine Clonmel 10 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One tablet contains 10 mg of lercanidipine
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationDrug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017
Drug drug interactions highlighting P450 Cytochromes Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017 Financial Disclosures and Conflicts I have no financial disclosures nor conflicts concerning
More informationAxitinib (renal) Note: in some patients it may be appropriate to increase the dose to 6mg BD before increasing to 7mg BD.
Axitinib (renal) Indication Treatment of advanced renal cell carcinoma after failure of treatment with a first-line tyrosine kinase inhibitor (UK licensed indication states sunitinib) or a cytokine. (NICE
More informationSUMMARY OF PRODUCT CHARACTERISTICS. One film-coated tablet contains 20 mg lercanidipine hydrochloride, equivalent to 18.8 mg
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lerkanidipin Actavis 10 mg film-coated tablet Lerkanidipin Actavis 20 mg film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationDONECEPT Tablets (Donepezil hydrochloride)
Published on: 22 Sep 2014 DONECEPT Tablets (Donepezil hydrochloride) Composition DONECEPT - 5 Each tablet contains: Donepezil hydrochloride equivalent to Donepezil 5 mg DONECEPT - 10 Each tablet contains:
More informationEFFECTIVE SHARED CARE AGREEMENT. July Dronedarone (Multaq ) For the treatment and management of atrial fibrillation
Whipps Cross University Hospital NHS Trust EFFECTIVE SHARED CARE AGREEMENT July 2011 Dronedarone (Multaq ) For the treatment and management of atrial fibrillation INTRODUCTION The Whipps Cross University
More informationValproate Case 3: Formulations Jose de Leon, MD
Valproate Case 3: Formulations 2-12-16 Jose de Leon, MD 3.Valproate Case 3 Described in J Clin Psychiatry 2004;65:724-5 http://www.ncbi.nlm.nih.gov/pubmed/15163266 Pharmacological explanation provided
More informationHow to Teach About Drugs and Aging
How to Teach About Drugs and Aging Brandon Koretz MD Assistant Clinical Professor Division of Geriatrics Challenges Prescription pad:internist::scalpel: Surgeon Artificial split between theory and practice
More informationDrug Interactions. Drug Interactions: Definition
Drug Interactions Scott R. Penzak, Pharm.D. Director, Clinical Pharmacokinetics Research Laboratory Clinical Center Pharmacy Department National Institutes of Health Drug Interactions: Definition The pharmacologic
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationAFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June
AFPC Conference 2009 InterMed-Rx : Harmony and optimal therapy in the use of medication June 5 2009 Jacques Turgeon, B.Pharm., Ph.D. Full professor, Faculty of pharmacy Research Director, CHUM Université
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationWHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?
ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics? Rex S. Lott, Pharm.D., BCPP Professor, ISU College of Pharmacy Mental Health Clinical Pharmacist, Boise VAMC
More informationCore Safety Profile: Midazolam Route of Administration Tablets Procedure: FR/H/PSUR/0026/001 Decemebr 2011
Core Safety Profile: Midazolam Route of Administration Tablets Procedure: FR/H/PSUR/0026/001 Decemebr 2011 4.2 Posology and method of administration Duration of treatment should be as short as possible.
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationUnderstanding the Drug Drug Interaction
Pharmacotherapeutics Understanding the Drug Drug Interaction Dong Seok Yim, M.D. Department of Pharmacology The Catholic University of Korea, College of Medicine E mail : yimds@catholic.ac.kr Abstract
More informationTranslation from Latvian Approved by SAM on Summary of Product Characteristics
Approved by SAM on 27.10.08 1. NAME OF THE MEDICINAL PRODUCT Eifilīns 150 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: Aminophylline (Aminophyllinum) Each tablet contains 150
More informationNECN Chemotherapy Handbook Protocol
DRUG ADMINISTRATION SCHEDULE Day Cycle length Drug Daily Dose Route Schedule Days 1 to 28 Continuous Erlotinib 150 mg Oral ONCE daily DOSE FORM Presented as 25mg, 100mg and 150mg Tablets CYCLE LENGTH AND
More informationEplerenone film-coated Tablets
Eplerenone film-coated Tablets 1.3 Product information 1.3.1 SPC, labelling and package leaflet 1.3.1.1 Summary of product characteristics Enclosed in subsequent pages, Module 1.3.1 Page 1 of 1 1. NAME
More informationQuetiapine Case 1 Warfarin Jose de Leon, MD
Quetiapine Case 1 Warfarin 1-23-16 Jose de Leon, MD 1. Quetiapine Case 1 J Clin Psychopharm 1999;19:382-3 http://www.ncbi.nlm.nih.gov/pubmed/10440472 Educational Objectives At the conclusion of this presentation,
More information2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY
PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY Darrell R. Abernethy, M.D., Ph.D. Associate Director for Drug Safety Office of Clinical Pharmacology
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Norvir 80 mg/ml oral solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of oral solution contains 80 mg of ritonavir.
More informationDrug-drug interactions in the elderly
December 08, 2016 Gerontopsychiatry CME, TAU Drug-drug interactions in the elderly Daniel Kurnik, MD Director of Clinical Pharmacology, Rambam Clinical Associate Professor, Technion Definition DDI: One
More informationCHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX
CHEMOTHERAPY PROTOCOL FOR ADMINISTRATION OF VENETOCLAX Therapeutic Indications: Venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion
More informationFood and Supplements Can Interfere With Medications
Nutrition Connection 1 HOUR CE CBDM Approved Food and Supplements Can Interfere With Medications by Mary D. Litchford, PhD, RD, LDN Do you feel confident identifying potential foods or dietary supplements
More informationITRANOX. Composition Each capsule contains :
ITRANOX Composition Each capsule contains : Itraconazole 100 mg Capsules Action Itraconazole is a synthetic triazole derivative. When administered orally, it has shown fungistatic activity against superficial
More informationElements for a Public Summary Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Acute pain usually responds to medication and should settle in less than three months. Inadequate pain relief may lead to other
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Prometazin Actavis 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 25 mg of promethazine
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationPharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )
Pharmacogenetic Testing in Psychiatry Jose de Leon, MD (12-01-15) Conflicts of Interest (See more details on conflict of interest in the first presentation Training Psychiatrists to Think like Pharmacologists
More informationDasatinib (SPIRIT 2 Trial)
Dasatinib (SPIRIT 2 Trial) SPIRIT2 - STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec or licensed generic) 400mg daily versus
More informationA clinical guide to managing drugdrug interactions in antiretroviral therapy
HIVPA 2008, 6 th June 2008 HIV Pharmacology and TDM B Marta Boffito MD PhD St. Stephen s Centre Chelsea and Westminster Hospital, London A clinical guide to managing drugdrug interactions in antiretroviral
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti-Cancer Treatment Protocol. Abiraterone. PROCTOCOL REF: MPHAABIRA (Version No: 1.
Systemic Anti-Cancer Treatment Protocol Abiraterone PROCTOCOL REF: MPHAABIRA (Version No: 1.0) Approved for use in: The treatment of metastatic castration resistant prostate cancer in adult men who are
More informationEplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
More information